Drug Trial Radar · NCT07226986
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
123
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Jul 10, 2028
Study completion Sep 13, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment.
Conditions
- PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions
AMO959Drug
DNA Damage Response inhibitor
AAA617Radiation
PSMA-targeted radiopharmaceutical
EnzalutamideDrug
Androgen receptor pathway inhibitor
AbirateroneDrug
Androgen receptor pathway inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence rate of Dose-limiting toxicities (DLTs)Time frame: Up to 42 days after the first AAA617 dose administration
- Phase Ib: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From date of start of study treatment, assessed up to approximately 45 months
- Phase Ib: Number of Participants with dose adjustmentsTime frame: From date of start of study treatment, assessed up to approximately 24 months
- Phase Ib: Dose IntensityTime frame: From date of start of study treatment, assessed up to approximately 24 months
- Phase Ib: Duration of exposure to each study drugTime frame: From date of start of study treatment, assessed up to approximately 24 months
- Phase II: Biochemical Response (PSA50)Time frame: From date of start of study treatment, assessed up to approximately 24 months
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
VA Greater LA Healthcare System
Los Angeles, California · Recruiting
Duke Univ Medical Center
Durham, North Carolina · Recruiting
Rio Grande Urology
El Paso, Texas · Recruiting
Utah Intermountain Medical Center
Murray, Utah · Recruiting
Novartis Investigative Site
Malvern, Victoria, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Murdoch, Western Australia, Australia · Recruiting
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Clermont-Ferrand, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Villejuif, France · Recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
München, Germany · Recruiting
Novartis Investigative Site
Stuttgart, Germany · Recruiting
Novartis Investigative Site
Dresden, Saxony, Germany · Recruiting
Novartis Investigative Site
Naples, Italy · Recruiting
Novartis Investigative Site
Cona, FE, Italy · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Fukuoka, Japan · Recruiting
Novartis Investigative Site
Sapporo, Hokkaido, Japan · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Granada, Andalusia, Spain · Recruiting
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.